Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 117   

Articles published

JNJ 108.25 +1.04 (0.97%)
price chart
Johnson amp; Johnsons Rezolsta Approved in the EU for HIV-1
Earlier this week, Johnson & Johnson's (JNJ - Analyst Report) subsidiary, Janssen, announced that it has gained EU approval for its HIV-1 drug, Rezolsta.
Related articles »  
How Will Johnson & Johnson's Ebola Investment Pay Off?
In early September, Johnson & Johnson stated that it was accelerating the development of a vaccine against the Zaire strain of the Ebola Virus that has been responsible for the current outbreak in Africa.
Related articles »  
Johnson & Johnson Seeks Payback In A Multi-Billion Trial With Boston Scientific
NEW YORK (Reuters) - Nearly a decade after losing a bidding war for device maker Guidant to Boston Scientific Corp, Johnson & Johnson finally has a chance for payback at a multibillion-dollar trial set to begin on Thursday. A federal court judge in New ...
Will Boston Scientific (BSX) Stock Be Hurt Today by Johnson & Johnson ...  TheStreet.com
J&J Seeks Billions in Trial Over Decade-Old Bidding War  Bloomberg
Related articles »  
Does Johnson & Johnson Still Fit With Warren Buffett's Investing Strategy?
Although Berkshire's portfolio is predominantly focused on financials, one healthcare stock that Buffett has been attracted to, and of which his company currently owns 327,100 shares equaling about $35.4 million dollars, is healthcare conglomerate ...
Related articles »  
Save the Children Named Johnson & Johnson's First "Enterprise Wide" Global ...
New York City, NY (Nov. 19, 2014) - Save the Children and Johnson & Johnson announced today a global partnership that has the potential to help millions of children over the next three years.
Johnson & Johnson Partners with Save the Children to Help Millions of ...  MarketWatch
Related articles »  
Johnson & Johnson May Settle 1000 More DePuy ASR Hip Claims for $250 M
On the heels of Johnson & Johnson's win this week in its Pinnacle Hip implant trial, the pharmaceutical giant may offer $250 million to settle lawsuits not included in its previous offer to settle thousands of DePuy ASR hip claims from last year ...
J&J May Pay $250 Million to Settle 1000 More Hip Claims  Bloomberg
Related articles »  
La Lumiere, with Johnson & Johnson's backing, expects big things from mask ...
Johnson & Johnson just invested $20 million in Jay Tapper's latest company, which has developed a mask that uses LED light to fight acne or wrinkles, depending on which version you buy.
Dividend Aristocrat: Johnson & Johnson (JNJ)
Johnson & Johnson (NYSE:JNJ) is a leading health care company with a diverse revenue base. Johnson & Johnson is also a member of the elite group of stocks called Dividend Aristocrats. To qualify, a company has to be part of the S&P 500 and have ...
Related articles »  
Johnson & Johnson buys electrolyte drink Orsl for Rs 750 crore
"This acquisition will allow us to expand our consumer health care offerings in line with our vision of helping consumers' lead healthy lives," said Thibaut Mongon, company group chairman, Johnson & Johnson Family of Consumer Companies Asia Pacific.
Johnson & Johnson (JNJ) Strikes $935 Million Deal With Geron Corporation ...
The pharmaceutical giant paid an upfront amount of $35 million for the rights to acquire the company's pipeline product which is, as of now, in early stages of development.
Related articles »